Oragenics, Inc. has entered into a new five year contract agreement with Randy Dennin and Associates, LLC (“RD & A”). Under the terms of the agreement, RD & A will be the exclusive distributor of Oragenics’ Oral Care Probiotics for Adults and Kids in Mexico under a private label. Both products will contain ProBiora3; Oragenics’ patented proprietary blend of three probiotics specifically designed for oral health.
Randy Dennin and Associates, LLC, established in 2009, with its international team of experts, is dedicated to navigating the challenging landscape of legislation and regulatory requirements for clients introducing new dietary supplements and health food products into global natural health markets. They champion initiatives that serve to provide more dietary supplements and health foods to consumers around the globe, with the ultimate goal of providing products which improve health and well-being. In order to assist with carrying out the introduction and distribution of the Oragenics’ product line under a private label, RD & A has recently established a partnership in Mexico with Great Health Incorporated. Great Health Incorporated and the Great Health brand will focus on increasing consumer demand for more health products that are viewed as natural, with an increased focus on prevention and consumer awareness in the use of dietary supplements.
"The completion of the agreement between Oragenics and RD & A is another step in the execution of our global strategy to become the world leader in probiotics for oral care. We are excited to add Mexico to the list of countries we are offering our unique patented ProBiora3® product specifically designed for oral health," stated Dr. John N Bonfiglio, president and CEO of Oragenics.
About Oragenics, Inc.
Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora3 in over 13 countries worldwide. In addition, Oragenics develops therapies designed to treat infectious diseases. More information about the company is available at www.oragenics.com.